Guangjun Shi

776 total citations
33 papers, 361 citations indexed

About

Guangjun Shi is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Guangjun Shi has authored 33 papers receiving a total of 361 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 13 papers in Oncology and 12 papers in Epidemiology. Recurrent topics in Guangjun Shi's work include Pancreatic and Hepatic Oncology Research (7 papers), Neuroendocrine Tumor Research Advances (6 papers) and Ferroptosis and cancer prognosis (5 papers). Guangjun Shi is often cited by papers focused on Pancreatic and Hepatic Oncology Research (7 papers), Neuroendocrine Tumor Research Advances (6 papers) and Ferroptosis and cancer prognosis (5 papers). Guangjun Shi collaborates with scholars based in China and United States. Guangjun Shi's co-authors include Xueying Tan, Zhen Yang, Nan Tang, Deguo Zhang, Ping Zhang, Dongxu Sun, Kun Ding, Weisheng Li, Chuanxu Wang and Mengya Wang and has published in prestigious journals such as Scientific Reports, Biochemical and Biophysical Research Communications and Annals of Surgical Oncology.

In The Last Decade

Guangjun Shi

32 papers receiving 355 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guangjun Shi China 11 187 104 98 90 82 33 361
Alessio Degiovanni Italy 12 121 0.6× 70 0.7× 59 0.6× 44 0.5× 85 1.0× 23 345
Katsuki Miyazaki Japan 12 126 0.7× 100 1.0× 54 0.6× 39 0.4× 73 0.9× 35 414
Guillaume B. Cardin Canada 11 184 1.0× 51 0.5× 81 0.8× 80 0.9× 40 0.5× 23 342
Annabella Di Mauro Italy 12 158 0.8× 90 0.9× 30 0.3× 55 0.6× 46 0.6× 41 401
Giovanna Forte Italy 11 213 1.1× 69 0.7× 61 0.6× 44 0.5× 50 0.6× 35 435
Fariborz Rashid-Kolvear Canada 9 254 1.4× 60 0.6× 86 0.9× 71 0.8× 82 1.0× 19 471
Noelia Agrá Spain 10 157 0.8× 49 0.5× 25 0.3× 83 0.9× 58 0.7× 13 311
Zhong Cheng China 13 221 1.2× 192 1.8× 70 0.7× 40 0.4× 98 1.2× 35 583
Feng Cao China 13 200 1.1× 151 1.5× 23 0.2× 43 0.5× 75 0.9× 33 385

Countries citing papers authored by Guangjun Shi

Since Specialization
Citations

This map shows the geographic impact of Guangjun Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guangjun Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guangjun Shi more than expected).

Fields of papers citing papers by Guangjun Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guangjun Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guangjun Shi. The network helps show where Guangjun Shi may publish in the future.

Co-authorship network of co-authors of Guangjun Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Guangjun Shi. A scholar is included among the top collaborators of Guangjun Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guangjun Shi. Guangjun Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Zhen, Tianhao Wu, Pengyu Chen, et al.. (2024). Recurrence Patterns and Long-Term Results After Curative Surgery for Patients With Breast Cancer. Annals of Surgical Oncology. 32(4). 2554–2568.
2.
Wang, Jian‐Ping, Peipei Cong, Lingli Liu, et al.. (2023). A novel prognostic signature for hepatocellular carcinoma based on SUMOylation-related genes. Scientific Reports. 13(1). 11233–11233. 3 indexed citations
3.
Yang, Zhen, et al.. (2023). Early-onset pancreatic neuroendocrine neoplasms: A distinct disease with improved survival compared with old individuals. Frontiers in Endocrinology. 14. 1025485–1025485. 3 indexed citations
5.
Tang, Nan, et al.. (2023). Development and verification of prognostic nomogram for ampullary carcinoma based on the SEER database. Frontiers in Oncology. 13. 1197626–1197626. 3 indexed citations
6.
Yang, Zhen, Kaiming Leng, & Guangjun Shi. (2023). Causes of death among patients with hepatocellular carcinoma in United States from 2000 to 2018. Cancer Medicine. 12(12). 13076–13085. 4 indexed citations
7.
Yang, Zhen, Dongsheng Zhang, & Guangjun Shi. (2022). Reappraisal of a 2-cm Cutoff Size for the Management of Nonfunctional Pancreatic Neuroendocrine Tumors: A Population-Based Study. Frontiers in Endocrinology. 13. 928341–928341. 4 indexed citations
9.
Yang, Zhen, Jie Liang, Kaiming Leng, & Guangjun Shi. (2022). Survival Benefit of Surgical Resection for Pancreatic Neuroendocrine Tumors With Oligometastatic Liver Metastasis: A Retrospective and Propensity Score-Matching Analysis. Frontiers in Oncology. 12. 903560–903560. 2 indexed citations
10.
Shi, Yongmei, et al.. (2022). A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma. Frontiers in Genetics. 13. 879299–879299. 7 indexed citations
11.
Yang, Zhen & Guangjun Shi. (2022). Comparative outcomes of pancreatic neuroendocrine neoplasms: A population-based analysis of the SEER database. European Journal of Surgical Oncology. 48(10). 2181–2187. 8 indexed citations
13.
Wang, Mengya, et al.. (2021). FNDC5 induces M2 macrophage polarization and promotes hepatocellular carcinoma cell growth by affecting the PPARγ/NF-κB/NLRP3 pathway. Biochemical and Biophysical Research Communications. 582. 77–85. 31 indexed citations
14.
Li, Luan, Siyao Liu, Chengzhen Li, et al.. (2021). Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma. BMC Cancer. 21(1). 331–331. 2 indexed citations
15.
Zhang, Deguo, Xueying Tan, Nan Tang, et al.. (2020). <p>Review of Research on the Role of Irisin in Tumors</p>. OncoTargets and Therapy. Volume 13. 4423–4430. 27 indexed citations
16.
Shi, Guangjun, Chuanliang Liu, Yiming Yang, et al.. (2019). Panx1 promotes invasion-metastasis cascade in hepatocellular carcinoma. Journal of Cancer. 10(23). 5681–5688. 21 indexed citations
17.
Zhang, Deguo, Luan Li, Nan Tang, et al.. (2019). <p>Irisin functions to inhibit malignant growth of human pancreatic cancer cells via downregulation of the PI3K/AKT signaling pathway</p>. OncoTargets and Therapy. Volume 12. 7243–7249. 22 indexed citations
18.
Shi, Guangjun, Chuanxu Wang, Ping Zhang, et al.. (2017). Donor Polymorphisms of Toll-like Receptor 4 rs1927914 Associated with the Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation. Archives of Medical Research. 48(6). 553–560. 14 indexed citations
19.
Shi, Guangjun, Nan Tang, Deguo Zhang, et al.. (2017). Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma. Biochemical and Biophysical Research Communications. 493(1). 585–591. 68 indexed citations
20.
Zhang, Ping, et al.. (2016). Ubiquitination is absolutely required for the degradation of hypoxia-inducible factor - 1 alpha protein in hypoxic conditions. Biochemical and Biophysical Research Communications. 470(1). 117–122. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026